Contraceptive app Natural Cycles, used by over 500K women, reported to regulator by Swedish hospital after reportedly causing 37 unwanted pregnancies
A contraceptive app used by more than 500,000 women has come under fire after reportedly causing 37 unwanted pregnancies.
Context & Ripple Effects
The regulator complaint lands just two months after Natural Cycles closed a $30M Series B led by EQT Ventures, turning a fast-scaling consumer app into a test case for whether software can be held to medical-device standards. The Swedish hospital's report over 37 unwanted pregnancies puts the company's core claim — that an algorithm tracking temperature can prevent conception — directly in front of its home-market regulator.
Effectiveness claims were already the company's soft spot: the UK's Advertising Standards Authority later banned a Natural Cycles Facebook ad for exaggerating how well the app works, and rival Clue pursued formal FDA clearance for its own digital contraceptive rather than relying on marketing claims.
First-order effects
- Natural Cycles now faces a regulatory review in Sweden while more than 500,000 women rely on it as their primary contraceptive method — any finding against the app threatens both its user base and the growth story behind its fresh funding.
- The reporting hospital has effectively escalated a clinical dispute into a compliance matter, forcing the company to defend its efficacy data to a regulator rather than to app-store reviewers.
Second-order effects
- Regulators beyond Sweden have a template to act on: the UK's ASA had already ruled a Natural Cycles ad misleading on effectiveness, so national bodies can now cite a documented pregnancy-failure case when policing fertility-app advertising.
- Competitors like Clue, which sought FDA clearance for a statistical ovulation-prediction contraceptive, gain a differentiation argument — certified validation versus consumer-grade claims — just as the category's credibility is questioned.
Third-order effects
- If the pattern holds, digital contraception splits into two tiers: apps that submit to medical-device clearance regimes and those relegated to wellness status, with funding and distribution concentrating in the former — a path Natural Cycles itself later followed toward FDA clearance and a larger user base.
- Scrutiny of what these apps do with intimate health data, already raised by reporting that many period trackers serve marketers more than users, is likely to fold into the same regulatory conversation as efficacy.
The trend: Fertility-tracking apps are being pushed from consumer-wellness marketing into regulated medical-device territory, with effectiveness evidence becoming the gate for funding, advertising, and survival.